Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients-Reference-Cited by-同舟云学术

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Published:2023-04-10 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Alcheikh Ahmad^ORCID,Perkins Griffith B.^ORCID,Pucar Phillippa A.,Cecchin Amelia,Chai Cheng Sheng,Tunbridge Matthew,Akerman Anouschka,Aggarwal Anupriya,Milogiannakis Vanessa,Turville Stuart,Allen Sharon,Hissaria Pravin,Banovic Tatjana,Coates P. Toby,Ross David M.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00824-8.pdf

Reference15 articles.

1. Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. Untwining anti-tumor and immunosuppressive effects of JAK inhibitors—a strategy for hematological malignancies? Cancers 2021;13:2611.

2. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021;14:119.

3. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–92.

4. Caocci G, Mulas O, Mantovani D, Costa A, Galizia A, Barabino L, et al. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Ann Hematol. 2022;101:929–31.

5. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia 2021;35:485–93.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies;Internal Medicine Journal;2023-12-25

2. Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy;2023-12-05

3. COVID and the Kidney: An Update;Seminars in Nephrology;2023-09